← Browse by Condition
Medical Condition

advanced solid tumor

Total Trials
30
Recruiting Now
30
Trial Phases
Phase 1, Phase 1, Phase 2

ClinicalMetric tracks all active clinical trials for advanced solid tumor sourced from ClinicalTrials.gov. Research in this area spans early-phase safety investigations through large Phase 3 confirmatory trials, conducted by NIH-funded academic centers, independent investigators, and pharmaceutical sponsors worldwide. Each listing is updated daily as new studies open enrollment and existing ones reach capacity or complete follow-up.

Trial listings include the NCT identifier, current recruitment status, phase classification, primary and secondary endpoints, estimated enrollment size, participating countries, and direct links to the full protocol on ClinicalTrials.gov. Eligibility criteria — including age range, disease stage, and prior treatment requirements — are documented for every study to help patients and clinicians assess suitability before contacting a trial site.

Frequently Asked Questions — advanced solid tumor Clinical Trials

How many clinical trials are currently recruiting for advanced solid tumor?
ClinicalMetric currently tracks 30 actively recruiting clinical trials for advanced solid tumor, sourced in real time from ClinicalTrials.gov. The total number of registered studies—including those not yet enrolling or in active follow-up—is 30. Trial availability changes daily as new studies open enrollment and existing ones reach capacity.
What trial phases are available for advanced solid tumor?
advanced solid tumor research spans Phase 1 (30 trials), Phase 2 (8 trials). Phase 1 studies evaluate safety and dosing in small groups, Phase 2 studies assess preliminary efficacy in 100–300 participants, and Phase 3 trials compare the new treatment against the standard of care in 300–3,000+ patients. Phase 4 post-approval studies monitor long-term outcomes in real-world populations.
How do I find out if I qualify for a advanced solid tumor clinical trial?
Eligibility criteria for advanced solid tumor trials vary by study and typically specify age range, disease stage or severity, prior treatment history, and specific diagnostic or laboratory parameters. Each listing on ClinicalMetric links to the full protocol on ClinicalTrials.gov, where inclusion and exclusion criteria are documented. Contact the sponsoring site's research coordinator directly to confirm your eligibility—your treating physician or specialist can also help identify the most appropriate trial based on your medical history and current treatment status.
Trial Phases
Phase 1
30
Phase 2
8
Top Sponsors
Shanghai Hengrui Pharmaceutical Co., Ltd. 1 trial
MOMA Therapeutics 1 trial
Ascentage Pharma Group Inc. 1 trial
Xenothera SAS 1 trial
GI Innovation, Inc. 1 trial

Recruiting Clinical Trials

NCT05836948 Phase 1
Recruiting
The Clinical Study of SHR-9839 for Injection in Patients With Advanced Solid Tumors
Enrollment
174 pts
Location
China
Sponsor
Shanghai Hengrui Pharmaceutica...
View Trial →
NCT06974110 Phase 1
Recruiting
Study of Orally Administered MOMA-341 in Participants With Advanced or Metastatic Solid Tumors
Enrollment
132 pts
Location
United States, Austr...
Sponsor
MOMA Therapeutics
View Trial →
NCT04785196 Phase 1, Phase 2
Recruiting
APG-115 in Combination With PD-1 Inhibitor in Patients With Advanced Liposarcoma or Advanced Solid Tumors
Enrollment
95 pts
Location
China
Sponsor
Ascentage Pharma Group Inc.
View Trial →
NCT06154291 Phase 1, Phase 2
Recruiting
FIH XON7 in Advanced/Metastatic Solid Tumors
Enrollment
255 pts
Location
Belgium, France
Sponsor
Xenothera SAS
View Trial →
NCT05824975 Phase 1, Phase 2
Recruiting
A Study to Evaluate the Safety and Therapeutic Activity of GI-102 As a Single Agent and in Combination with Conventional Anti-cancer Drugs, Pembrolizumab or Trastuzumab Deruxtecan(T-DXd) in Patients with Advanced Solid Tumors (KEYNOTE-G08)
Enrollment
358 pts
Location
United States, South...
Sponsor
GI Innovation, Inc.
View Trial →
NCT04855435 Phase 1
Recruiting
Safety and Preliminary Efficacy of MBS8(1V270) in Cancer Patients With Advanced Solid Tumours
Enrollment
106 pts
Location
Denmark, Spain
Sponsor
MonTa Biosciences ApS
View Trial →
NCT05329103 Phase 1
Recruiting
A Study to Evaluate PEEL-224 in Patients With Advanced Solid Tumors
Enrollment
65 pts
Location
United States
Sponsor
Peel Therapeutics Inc
View Trial →
NCT05495295 Phase 1
Recruiting
First-in-human Trial of PhOx430, a First-in-class Acetylglucosaminyltransferase V Inhibitor, in Advanced Solid Tumours
Enrollment
149 pts
Location
France, Italy
Sponsor
Phost'In Therapeutics
View Trial →
NCT05156203 Phase 1
Recruiting
Safety and Tolerability Study for T-1301 Capsules to Treat Advanced Solid Tumors
Enrollment
30 pts
Location
Taiwan
Sponsor
Taivex Therapeutics Corporatio...
View Trial →
NCT06132503 Phase 1
Recruiting
Safety, Pharmacokinetics, and Clinical Activity of LP-284 in Adult Patients With Relapsed or Refractory Lymphomas and Solid Tumors
Enrollment
110 pts
Location
United States
Sponsor
Lantern Pharma Inc.
View Trial →
NCT05983523 Phase 1
Recruiting
A Study of PEP07 (Checkpoint Kinase 1 Inhibitor) in Patients with Advanced or Metastatic Solid Tumors
Enrollment
54 pts
Location
Taiwan
Sponsor
PharmaEngine
View Trial →
NCT06072989 Phase 1
Recruiting
Repeat Intravenous Infusions of B4T2-001 CAR-T Without Lymphodepleting Chemotherapy for Solid Tumors
Enrollment
24 pts
Location
China
Sponsor
Shanghai East Hospital
View Trial →
NCT06959615 Phase 1, Phase 2
Recruiting
A Phase I/IIa Study of JAB-23E73 in Patients With Advanced Solid Tumors Harboring KRAS Gene Alteration
Enrollment
334 pts
Location
China
Sponsor
Jacobio Pharmaceuticals Co., L...
View Trial →
NCT06108050 Phase 1
Recruiting
JZP898 Intravenous Infusion as Monotherapy and Combination With Pembrolizumab in Adults With Advanced/Metastatic Solid Tumors
Enrollment
177 pts
Location
United States
Sponsor
Jazz Pharmaceuticals
View Trial →
NCT06561685 Phase 1
Recruiting
A Study of LY4050784 in Participants With Advanced or Metastatic Solid Tumors
Enrollment
340 pts
Location
United States, Franc...
Sponsor
Eli Lilly and Company
View Trial →
NCT07256782 Phase 1, Phase 2
Recruiting
A Study of QLC5508 Combinations in Patients With Advanced Solid Tumors
Enrollment
444 pts
Location
China
Sponsor
Qilu Pharmaceutical Co., Ltd.
View Trial →
NCT06197139 Phase 1
Recruiting
A Clinical Study of [177Lu]Lu-XT117 Injection in Patients With Advanced Solid Tumors
Enrollment
20 pts
Location
China
Sponsor
Xinlu Wang
View Trial →
NCT06716619 Phase 1
Recruiting
A Phase I Trial of Tumor-Associated Lymph Node T-Cell Injection With Advanced Malignant Solid Tumors
Enrollment
32 pts
Location
China
Sponsor
Guangzhou FineImmune Biotechno...
View Trial →
NCT05768932 Phase 1
Recruiting
BAL0891 in Patients With Advanced Solid Tumors or Relapsed or Refractory Acute Myeloid Leukemia
Enrollment
260 pts
Location
United States, South...
Sponsor
SillaJen, Inc.
View Trial →
NCT05098132 Phase 1, Phase 2
Recruiting
Study of STK-012 Alone and With Other Treatments in Patients With Advanced Lung Cancer and Other Cancers
Enrollment
364 pts
Location
United States, Georg...
Sponsor
Synthekine
View Trial →
NCT06672185 Phase 1
Recruiting
ARC101 in Advanced Solid Tumors
Enrollment
70 pts
Location
United States, Austr...
Sponsor
Third Arc Bio
View Trial →
NCT06641908 Phase 1
Recruiting
Anti-GD2 ADC M3554 in Advanced Solid Tumors
Enrollment
52 pts
Location
United States, Belgi...
Sponsor
EMD Serono Research & Developm...
View Trial →
NCT05978102 Phase 1, Phase 2
Recruiting
A Dose Escalation and Dose Expansion Clinical Study of STI-7349 in Subjects With Advanced Solid Tumors
Enrollment
183 pts
Location
China
Sponsor
The Fourth Affiliated Hospital...
View Trial →
NCT06220864 Phase 1
Recruiting
SNV1521 in Participants With Advanced Solid Tumors
Enrollment
400 pts
Location
United States, Austr...
Sponsor
Synnovation Therapeutics, Inc.
View Trial →
NCT07098299 Phase 1
Recruiting
Metformin Combined With Chemotherapy and/or Immunotherapy in Solid Malignancies
Enrollment
60 pts
Location
United States
Sponsor
Barbara Ann Karmanos Cancer In...
View Trial →
NCT06298058 Phase 1
Recruiting
A Clinical Trial of SIBP-A13 Injection in the Treatment of Advanced Malignant Solid Tumor Patients.
Enrollment
144 pts
Location
China
Sponsor
Shanghai Institute Of Biologic...
View Trial →
NCT06211647 Phase 1
Recruiting
A Clinical Study of [177Lu]Lu-XT117 Injection in Patients With Advanced Solid Tumors
Enrollment
20 pts
Location
China
Sponsor
Ruimin Wang
View Trial →
NCT04740398 Phase 1
Recruiting
A Study of CBP-1008 in Patients With Advanced Solid Tumor
Enrollment
143 pts
Location
China
Sponsor
Coherent Biopharma (Suzhou) Co...
View Trial →
NCT05367778 Phase 1, Phase 2
Recruiting
Phase 1/2 Study of HS-10370 in Patients with Advanced Solid Tumors
Enrollment
176 pts
Location
China
Sponsor
Jiangsu Hansoh Pharmaceutical ...
View Trial →
NCT07541573 Phase 1
Recruiting
GTB-5550 in Advanced Solid Tumors
Enrollment
175 pts
Location
United States
Sponsor
Masonic Cancer Center, Univers...
View Trial →

Related Conditions

metastatic solid tumor (5) gastric cancer (2) metastatic cancer (2) cutaneous melanoma (2) non small cell lung cancer (2) endometrial cancer (1) msi h cancer (1) colorectal cancer (1) dmmr cancer (1) liposarcoma (1) soft tissue sarcoma sts (1) platinum resistant ovarian cancer proc (1)
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology